Annual Accounts Receivable
$129.19 M
+$78.09 M+152.84%
December 31, 2024
Summary
- As of March 12, 2025, TGTX annual accounts receivable is $129.19 million, with the most recent change of +$78.09 million (+152.84%) on December 31, 2024.
- During the last 3 years, TGTX annual accounts receivable has risen by +$127.80 million (+9200.58%).
- TGTX annual accounts receivable is now at all-time high.
Performance
TGTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$129.19 M
+$13.46 M+11.63%
December 31, 2024
Summary
- As of March 12, 2025, TGTX quarterly accounts receivable is $129.19 million, with the most recent change of +$13.46 million (+11.63%) on December 31, 2024.
- Over the past year, TGTX quarterly accounts receivable has stayed the same.
- TGTX quarterly accounts receivable is now at all-time high.
Performance
TGTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
TGTX Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +152.8% | 0.0% |
| 3 y3 years | +9200.6% | 0.0% |
| 5 y5 years | - | 0.0% |
TGTX Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | -100.0% | at high | -100.0% |
| 5 y | 5-year | at high | -100.0% | at high | -100.0% |
| alltime | all time | at high | -100.0% | at high | -100.0% |
TG Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $129.19 M(+152.8%) | $129.19 M(+11.6%) |
| Sep 2024 | - | $115.73 M(+38.4%) |
| Jun 2024 | - | $83.61 M(+28.7%) |
| Mar 2024 | - | $64.98 M(+27.2%) |
| Dec 2023 | $51.09 M(>+9900.0%) | $51.09 M(+29.9%) |
| Sep 2023 | - | $39.32 M(+124.9%) |
| Jun 2023 | - | $17.48 M(+102.8%) |
| Mar 2023 | - | $8.62 M(>+9900.0%) |
| Dec 2022 | $0.00 | $0.00(0.0%) |
| Sep 2022 | - | $0.00(-100.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $88.00 K(-90.3%) |
| Mar 2022 | - | $903.00 K(-35.0%) |
| Dec 2021 | $1.39 M(>+9900.0%) | $1.39 M(+0.4%) |
| Sep 2021 | - | $1.38 M(+48.7%) |
| Jun 2021 | - | $931.00 K(+20.8%) |
| Mar 2021 | - | $771.00 K(>+9900.0%) |
| Dec 2020 | $0.00(-100.0%) | $0.00(-100.0%) |
| Jun 2002 | - | $501.70 K(+159.9%) |
| Dec 2000 | $193.00 K(-35.7%) | $193.00 K(-35.7%) |
| Dec 1999 | $300.00 K | $300.00 K |
FAQ
- What is TG Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for TG Therapeutics?
- What is TG Therapeutics annual accounts receivable year-on-year change?
- What is TG Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for TG Therapeutics?
- What is TG Therapeutics quarterly accounts receivable year-on-year change?
What is TG Therapeutics annual accounts receivable?
The current annual accounts receivable of TGTX is $129.19 M
What is the all time high annual accounts receivable for TG Therapeutics?
TG Therapeutics all-time high annual accounts receivable is $129.19 M
What is TG Therapeutics annual accounts receivable year-on-year change?
Over the past year, TGTX annual accounts receivable has changed by +$78.09 M (+152.84%)
What is TG Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of TGTX is $129.19 M
What is the all time high quarterly accounts receivable for TG Therapeutics?
TG Therapeutics all-time high quarterly accounts receivable is $129.19 M
What is TG Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, TGTX quarterly accounts receivable has changed by $0.00 (0.00%)